This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the following investor conferences:
Wedbush Lifesciences Management Access Conference on Tuesday, August 13, 2013 at 3:40 p.m. ET in New York, New York
Canaccord Genuity 33rd Annual Growth Conference on Wednesday, August 14, 2013 at 4:30 p.m. ET in Boston, Massachusetts
The events will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website at
www.anacor.com. A replay will also be available for three months following the presentation.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. We have also discovered three other compounds that we have out-licensed for further development — two are licensed to Eli Lilly and Company for the treatment of animal health indications and the third compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness). We also have a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit